免疫检查点抑制剂在转移性去势抵抗性前列腺癌中的新兴作用:系统综述
本系统综述检索截至2020年9月的文献,评估免疫检查点抑制剂(ICI)联合其他疗法治疗转移性去势抵抗性前列腺癌(mCRPC)的潜在作用。
要点
- 临床前证据提示ICI联合其他疗法可能增强mCRPC疗效。
- 多数研究聚焦ICI联合疫苗、ADT、化疗、PARP抑制、放疗或PSMA靶向放射配体治疗。
- 尚无III期试验最终结果,缺乏长期结局的1级证据支持联合治疗。
核心结论
- 临床前和临床试验表明免疫治疗与标准mCRPC治疗联合可能产生协同效应。
- 仍需更好理解机制和最佳治疗方式。
- 尚无III期试验报告最终结果,无1级证据支持ICI联合mCRPC疗法。
研究设计与样本
- 系统综述,检索Medline和科学会议记录,时间截至2020年9月,遵循PRISMA指南。
- 通过ClinicalTrials.gov系统检索正在进行的免疫治疗联合标准mCRPC治疗试验。
主要发现
- 临床前证据提示联合策略可能增强ICI在PC患者中的疗效。
- 这导致了超过50项基于免疫治疗的临床试验设计。
- 多数研究聚焦ICI联合疫苗、雄激素剥夺治疗、化疗、PARP抑制、放疗和PSMA引导放射配体治疗。
- 初步分析报告ICI联合其他抗癌疗法有前景的发现。
- 尚无III期试验报告最终结果,无长期结局的1级证据支持ICI联合mCRPC疗法。
临床怎么用
- 当前证据支持免疫治疗药物若与其他治疗联合可能在mCRPC中有效的假设。
- 仍需等待正在进行的试验结果,才能将这一新治疗方式用于日常实践。
局限性
- 尚无III期试验报告最终结果,缺乏长期结局的1级证据。
- 需要更好理解机制和最佳治疗方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The role of immune checkpoint inhibition (ICI) in the treatment of prostate cancer (PC) still remains elusive. It has been proposed that combination of ICI with other molecules increases the efficacy of immunotherapy in PC. OBJECTIVE: To systematically review the literature to assess the potential role of ICI in combination with additional therapies for the management of metastatic castration-resistant PC (mCRPC). EVIDENCE ACQUISITION: A systematic review using Medline and scientific meeting records was carried out in September 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. Ongoing trials of immunotherapy with standard mCRPC therapeutics were identified via a systematic search on ClinicalTrials.gov. EVIDENCE SYNTHESIS: A total of five full-text papers, ten congress abstracts, and 15 trials on ClinicalTrials.gov were identified. Preclinical evidence suggests that combinational approaches might be considered to enhance the efficacy of ICI in PC patients. This led to the design of more than 50 immunotherapy-based clinical trials. The majority of the studies focus on ICI combinations with vaccines, androgen deprivation therapy, chemotherapy, PARP inhibition, radiotherapy, and prostate-specific membrane antigen-guided radioligand therapy. Preliminary analyses reported promising findings for the use of ICI in combination with other anticancer therapies. However, no phase 3 trial has yet reported final results, so no level 1 evidence with long-term outcomes currently supports the combination of ICI with mCRPC therapies. CONCLUSIONS: Preclinical and clinical trials have demonstrated that combining immunotherapy with standard mCRPC treatment options has the potential to provide a synergistic effect. Nonetheless, a better understanding of the mechanism and of the optimal treatment approach is still needed. PATIENT SUMMARY: We reviewed the literature on immunotherapy in combination with standard treatments for patients with metastatic castration-resistant prostate cancer (mCRPC). Current evidence supports the hypothesis that immunotherapeutic drugs might be effective in mCRPC if combined with other treatment options. However, results of ongoing trials are still awaited before this novel treatment approach can be implemented in the daily practice.
引用
- Heidegger I, Necchi A, Pircher A, et al. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? Eur Urol Oncol. 2020. PMID: 33243663. doi:10.1016/j.euo.2020.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。